PHOENIX (3TV/CBS 5) -- The fight against Alzheimer's has been a long and frustrating one, but the researchers at Barrow Neurological Center are hoping to make some progress.
They're opening up a new clinical trial to tackle the disease in a different way.
It's called the T2 Protect AD trial.
The drug they're using is called Troriluzole and it normalizes high levels of glutamate in the brain.
Glutamate can damage brain cells leading to memory problems.
[READ MORE: CBS 5 This Morning stories]
Doctor Anna Burke says unlike other therapies, this one does not focus on amyloid plaque.
"So T2 Protect, rather than focusing on amyloid plaque, focuses on a neurotransmitter called glutamate that in excessive amounts can cause damage to the brain cells and by decreasing the glutamate in the brain, in theory, reduces neurotoxicity and maintains brain health," she explained.
The hope is that the medication they're using will help protect against, slow down or even improve memory and thinking problems.
If you or someone you know is in the early or moderate stages of Alzheimer's disease you may be eligible for this trial.
[RELATED: Alzheimer's vaccine shows promise]
They need people 50 to 85 years of age.
The trial runs 48 weeks and it's completely paid for.
For more information call 1-800-392-2222.